The Cremins lab investigates the epigenetic mechanisms regulating development and function of the mammalian central nervous system. We map and analyze neuronal epigenomes in three-dimensions using quantitative, genome-wide technologies. We also perturb epigenomes by employing state-of-the art genetic engineering strategies (e.g. CRISPR/Cas9, optoepigenetics). To test our hypotheses, we primarily use embryonic and induced pluripotent stem cell models of neuronal differentiation and disease. Our long-term goal is to discover how genome architecture controls genome function, applying this to study fundamental mechanisms controlling neuronal phenotype and, by extension, the onset and progression of neurodegenerative and neurodevelopmental disease states.

Danying Guan joins the lab for the summer as part of the
The American Physician Scientists Association (APSA) Virtual Summer Research Program. Welcome Danying!

Congratulations to Ali Nikish for passing her Ph.D. qualifying exam!

Noah Barnett, David Barto, Ashley Cook, Nathan Ehrenreich, Thomas Malachowski, and Ken Raanin Chandradoss have officially joined the lab. Welcome!

Congratulations to Kate Titus for passing her Ph.D. qualifying exam!

Jon Beagan presents at a virtual conference sponsored by Arima alongside
Dan Geschwind and Schahram Akbarian

Jon Beagan wins the 2020 Sol Pollack award for the PhD thesis
representing original research at the forefront of its field.

Miriam Minsk and Kelly Feng wrap up their junior year after conquering
the challenging Covid-19 virtual semester. Miriam and Kelly – we are so
proud of you.

Jennifer gives a virtual seminar at New York University

Jennifer speaks on the lab’s work at Cold Spring Harbor Biology of
Genomes virtual meeting

Jennifer speaks on the lab’s work at Cold Spring Harbor Genome
Organization virtual meeting



Our work is supported by the New York Stem Cell Foundation, the Alfred P. Sloan Foundation, the National Science Foundation, an NIH New Innovator Award through the National Institute of Mental Health and the NIH 4D Nucleome Common Fund Initiative.